Serum levels of soluble interleukin-2 receptors and their relation to lymphocyte subpopulations in patients with metastatic solid tumours

Lissoni, Paolo; Barni, Sandro; Rescaldani, R; Rovelli, F; Tancini, G

doi:10.1038/bjc.1989.325

Cited by 12 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High concentrations of soluble IL-2 receptor and C-reactive protein in most of the patients who had metastases at presentation suggests an inflammatory response perhaps due to tumour burden and confirms studies in other neoplasms [17]. Immune activation would be expected to be accompanied by the secretion of cytokines such as IL1-a, ILl-p, IL6, TNF-a, TNF-P and IFN-y.…”

Section: Discussionsupporting

confidence: 70%

Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy

Dadian¹,

Riches²,

Henderson³

et al. 1994

British Journal of Urology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 70%

Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy

Dadian¹,

Riches²,

Henderson³

et al. 1994

British Journal of Urology

View full text Add to dashboard Cite

show abstract

“…Immunologically these highly regulated processes are essential for antigen presentation, extravasation of leucocytes across activated vascular endothelium and the delivery of cytotoxic "hits" to a target cell. Several reports have described soluble forms of cell adhesion molecules whose functions remain largely undetermined (Lisoni et al, 1989;Shijubo et al, 1992). In this study we report the secretion of soluble forms of ICAM-1 in the urine of patients receiving intravesical BCG immunotherapy for superficial high-grade carcinoma in situ of the bladder.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, production of SICAM-I is heterogeneous as some patients fail to produce any at all. If the source of SICAM-I is the bladder tumour per se, then its detection in Several forms of non-cytokine, potentially immunologically relevant soluble molecules have been identified, often in the sera of normal individuals or in that of patients with malignancies or chronic pathological states (Lisoni et al, 1989;Shijubo et al, 1992). Such molecules include soluble cytokine receptors, soluble MHC molecules and, more recently, soluble cellular adhesion molecules (SCAM) such as E-selectin and the intercellular adhesion molecule-1 (ICAM-1) (Leeuwenberg et al, 1992).…”

mentioning

confidence: 99%

Expression and shedding of ICAM‐1 in bladder cancer and its immunotherapy

Jackson

Alexandrov

Gribben

et al. 1993

Intl Journal of Cancer

View full text Add to dashboard Cite

Intercellular adhesion molecule-1 (ICAM-1) is one of 3 major ligands for the beta 2 integrin leucocyte function-associated antigen-1 (LFA-1). Several reports have emerged describing soluble forms of ICAM-1 in association with normal and pathological states (e.g., malignancy). In this study we have identified the secretion of soluble ICAM-1 in tissue culture supernatants from bladder tumour monolayers and in the urine of patients receiving intravesical BCG immunotherapy for superficial bladder cancer. In vitro, small amounts of sICAM-1 were detected in the tissue culture supernatants of bladder cancer cells, known to constitutively express ICAM-1. Following stimulation with interferon gamma, the levels of sICAM-1 increased inversely to the levels of cell surface ICAM-1, suggesting sheeding. Induction and augmentation of cell surface ICAM-1 required de novo mRNA and protein synthesis. However, treatment with cycloheximide, after stimulation with IFN-gamma, resulted in increased levels of membrane associated ICAM-1. Correspondingly, the level of sICAM-1 in the supernatant was low in comparison with controls, suggesting that cycloheximide acted via stabilization of membrane ICAM-1 or via prevention of some enzymatic cleavage event. In vivo, sICAM-1 can be detected at high levels in patients' urine following immunotherapy of bladder cancer with intravesically administered BCG organisms. Production of sICAM-1 is transient and occurs only in the first 12 hr following installation. Furthermore, production of sICAM-1 is heterogeneous as some patients fail to produce any at all. If the source of sICAM-1 is the bladder tumour per se, then its detection in urine could indicate a response of the tumour to immunotherapy and indeed may prove a useful indicator of clinical response.

show abstract

Spontaneous regression of metastatic renal cell carcinoma following palliative irradiation of the primary tumour

MacManus¹,

Harte²,

Stranex³

1994

I.J.M.S.

View full text Add to dashboard Cite

A 58 years old man presented with a bulky renal primary tumour, paratracheal lymphadenopathy and multiple pulmonary metastases. Spontaneous regression of intrathoracic metastases occurred after low dose palliative irradiation of the primary tumour. Serum levels of Interleukin-2 receptor were elevated during the period of tumour regression but concentrations of other cytokines were normal. Progressive abdominal disease eventually caused death. Autopsy confirmed the presence of renal cell carcinoma with intrathoracic metastases.

show abstract

Serum levels of soluble interleukin-2 receptors and their relation to lymphocyte subpopulations in patients with metastatic solid tumours

Cited by 12 publications

References 6 publications

Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy

Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy

Expression and shedding of ICAM‐1 in bladder cancer and its immunotherapy

Spontaneous regression of metastatic renal cell carcinoma following palliative irradiation of the primary tumour

Contact Info

Product

Resources

About